Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

DISEASE CHARACTERISTICS:

Histologically or cytologically confirmed metastatic or unresectable cancer largely confined to the peritoneal cavity

Fully resected and/or electrocauterized metastatic disease involving the peritoneum (stage IV, no residual disease) allowed
No known brain metastases

PATIENT CHARACTERISTICS:

Age:

18 and over

Performance status:

ECOG 0-2

Life expectancy:

Not specified

Hematopoietic:

WBC at least 3,000/mm^3
Absolute neutrophil count at least 1,500/mm^3
Platelet count at least 100,000/mm^3

Hepatic:

Bilirubin normal
SGOT/SGPT no greater than 2.5 times upper limit of normal

Renal:

Creatinine normal OR
Creatinine clearance at least 60 mL/min

Cardiovascular:

No symptomatic congestive heart failure
No unstable angina pectoris
No cardiac arrhythmia

Other:

No history of allergy to platinum compounds or antiemetics that would preclude study
No other uncontrolled illness (e.g., active infection)
No evidence of neuropathy
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered

Endocrine therapy:

Not specified

Radiotherapy:

At least 4 weeks since prior radiotherapy and recovered

Surgery:

See Disease Characteristics

Other:

No other concurrent investigational agents
No concurrent antiretroviral therapy (HAART)